Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

Vir Bio (VIR) reveals 24-week post-end-of-treatment data from a mid-stage trial for its Hep B therapy developed with Xencor ...

Experts highlight ten common requests received in their Gastroenterology advice and guidance service and explain how these ...

Functional cure, defined as durable hepatitis B surface antigen (HBsAg ... and predicting a lower risk of HBeAg-negative hepatitis and liver fibrosis in adulthood." "In this study, we further ...

Conclusion: Cirrhotic CHB patients had lower antibody titers to inactivated SARS-CoV-2 vaccines ... The inclusion criteria were as follows: a) over 18 years of age; b) were positive for hepatitis B ...

2020). Glembatumumab vedotin (CDX-011) consists of a glembatumumab antibody that is linked to monomethyl auristatin E via a protease-sensitive linker. Glembatumumab targets glycoprotein NMB, and it is ...

1st Hepatitis B Surface Antibody Titer (to follow completion of Hep B vaccination series). Must be drawn > 4 weeks from last dose: $15 If titer is negative, completion of second Hep B series is ...